PMID- 37546519 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230808 IS - 1176-6328 (Print) IS - 1178-2021 (Electronic) IS - 1176-6328 (Linking) VI - 19 DP - 2023 TI - Serum Levels of Tumor Necrosis Factor-alpha and Vascular Endothelial Growth Factor in the Subtypes of Clinical High Risk Individuals: A Prospective Cohort Study. PG - 1711-1723 LID - 10.2147/NDT.S418381 [doi] AB - INTRODUCTION: Numerous studies have established the roles of inflammation and angioneurins in the pathogenesis of schizophrenia (SCZ). This study aimed to compare the serum levels of tumour necrosis factor (TNF)-alpha and vascular endothelial growth factor (VEGF) in patients at clinical high risk (CHR) for psychosis or SCZ at baseline and one year after treatment. METHODS: A total of 289 CHR participants from the Shanghai At Risk for Psychosis Extended Program (SHARP) were tracked for a year. They were divided into two and four subtypes based on symptom severity according to the Structured Interview for Prodromal Syndromes (SIPS) and received standard medical care. At baseline and one-year follow-up, TNF-alpha and VEGF were detected using enzyme-linked immunosorbent assay, and pathological features were assessed using the Global Assessment of Function (GAF) score. RESULTS: Baseline TNF-alpha levels did not differ significantly, while VEGF levels were lower in patients with more severe symptoms. VEGF showed a negative correlation with negative features, both overall (r = -0.212, p = 0.010) and in the subgroup with higher positive scores (r = -0.370, p = 0.005). TNF-alpha was positively correlated with negative symptoms in the subgroup with higher negative scores (r = 0.352, p = 0.002). A three-way multivariate analysis of variance demonstrated that participants in Subtype 1 of positive or negative symptoms performed better than those in Subtype 2, with significant main effects and interactions of group and both cytokines. DISCUSSION: TNF-alpha and VEGF levels are higher and lower, respectively, in CHR patients with more severe clinical symptoms, particularly negative symptoms, which point to a worsening inflammatory and vascular status in the brain. CI - (c) 2023 Ye et al. FAU - Ye, JiaYi AU - Ye J AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. FAU - Wei, YanYan AU - Wei Y AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. FAU - Zeng, JiaHui AU - Zeng J AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. FAU - Gao, YuQing AU - Gao Y AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. FAU - Tang, XiaoChen AU - Tang X AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. FAU - Xu, LiHua AU - Xu L AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. FAU - Hu, YeGang AU - Hu Y AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. FAU - Liu, XiaoHua AU - Liu X AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. FAU - Liu, HaiChun AU - Liu H AD - Department of Automation, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China. FAU - Chen, Tao AU - Chen T AD - Big Data Research Lab, University of Waterloo, Ontario, Canada. AD - Labor and Worklife Program, Harvard University, Cambridge, MA, USA. FAU - Li, ChunBo AU - Li C AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. FAU - Zeng, LingYun AU - Zeng L AD - Department of Psychiatric Rehabilitation, Shenzhen Kangning Hospital, ShenZhen, GuangDong, People's Republic of China. FAU - Wang, JiJun AU - Wang J AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. AD - Center for Excellence in Brain Science and Intelligence Technology (CEBSIT), Chinese Academy of Science, Shanghai, People's Republic of China. AD - Institute of Psychology and Behavioral Science, Shanghai Jiao Tong University, Shanghai, People's Republic of China. FAU - Zhang, TianHong AU - Zhang T AUID- ORCID: 0000-0002-5379-7119 AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China. LA - eng PT - Journal Article DEP - 20230731 PL - New Zealand TA - Neuropsychiatr Dis Treat JT - Neuropsychiatric disease and treatment JID - 101240304 PMC - PMC10402730 OTO - NOTNLM OT - TNF-alpha OT - VEGF OT - inflammation OT - prodromal psychosis OT - ultra high risk COIS- All authors confirm that there are no competing interests to disclose in this work. EDAT- 2023/08/07 06:41 MHDA- 2023/08/07 06:42 PMCR- 2023/07/31 CRDT- 2023/08/07 04:38 PHST- 2023/04/23 00:00 [received] PHST- 2023/07/24 00:00 [accepted] PHST- 2023/08/07 06:42 [medline] PHST- 2023/08/07 06:41 [pubmed] PHST- 2023/08/07 04:38 [entrez] PHST- 2023/07/31 00:00 [pmc-release] AID - 418381 [pii] AID - 10.2147/NDT.S418381 [doi] PST - epublish SO - Neuropsychiatr Dis Treat. 2023 Jul 31;19:1711-1723. doi: 10.2147/NDT.S418381. eCollection 2023.